Package Leaflet: Information for the Patient
Paliperidona Teva 50 mg prolonged-release injectable suspension EFG
Paliperidona Teva 75 mg prolonged-release injectable suspension EFG
Paliperidona Teva 100 mg prolonged-release injectable suspension EFG
Paliperidona Teva 150 mg prolonged-release injectable suspension EFG
Starter Treatment Pack:
Paliperidona Teva 150 mg and Paliperidona Teva 100 mg prolonged-release injectable suspension EFG
Read the entire package leaflet carefully before you start using this medicine because it
contains important information for you.
Contents of the package leaflet
Paliperidona Teva contains the active substance paliperidone, which belongs to a class of medicines called antipsychotics, and is used as maintenance treatment for the symptoms of schizophrenia in adult patients who have been stabilised on paliperidone or risperidone.
If you have shown a response to paliperidone or risperidone in the past and have mild or moderate symptoms, your doctor may start treatment with Paliperidona Teva without prior stabilisation on paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are not normally present. For example, a person with schizophrenia may hear voices or see things that do not exist (called hallucinations), have false beliefs (called delusions) or have an abnormal distrust of others. Negative refers to the lack of behaviours or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimulus or may have difficulty speaking in a clear and logical manner. People with this disorder may also feel depressed, anxious, guilty or tense.
Paliperidona Teva can help alleviate the symptoms of your illness and prevent them from coming back.
Do not usepaliperidone
Warnings and precautions
Talk to your doctor, pharmacist or nurse before you start using Paliperidona Teva.
This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with other similar medicines may have an increased risk of stroke or death (see section 4, possible side effects).
All medicines can cause side effects and some of the side effects of this medicine may worsen the symptoms of other illnesses. For this reason, it is important that you discuss with your doctor any of the following illnesses, which may worsen during treatment with this medicine:
If you have any of these illnesses, please consult your doctor as it may be necessary to adjust your dose or keep you under observation for a period of time.
Because it has been very rarely observed in patients treated with this medicine that there is a dangerously low number of a type of white blood cell necessary to fight infections in the blood, your doctor may check your white blood cell count.
Even if you have previously tolerated oral paliperidone or risperidone, it is rare for allergic reactions to occur after receiving injections of Paliperidona Teva. Seek medical help immediately if you experience a skin rash, swelling of the throat, itching or breathing problems, as these may be signs of a severe allergic reaction.
This medicine may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with this medicine, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
Since this medicine can reduce the urge to vomit, there is a possibility that it may mask the body's normal response to the ingestion of toxic substances or other illnesses.
During eye surgery for cataracts, the pupil (the black circle in the centre of the eye) may not increase in size as needed. Additionally, the iris (the coloured part of the eye) may become flaccid during surgery and this may cause damage to the eye. If you are planning to have eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Children and adolescents
Do not use this medicine in children under 18 years of age.
Other medicines and Paliperidona Teva
Tell your doctor if you are using, have recently used or might use any other medicines.
Taking this medicine with carbamazepine (an anti-epileptic and mood stabiliser) may require a change in your dose of this medicine.
Since this medicine acts mainly on the brain, interaction with other medicines that also act on it may cause an exaggeration of side effects, such as drowsiness or other effects on the brain, such as other psychiatric medicines, opioids, antihistamines and sleeping medicines.
Since this medicine can lower blood pressure, you should be careful if you use this medicine with other medicines that also lower blood pressure.
This medicine may reduce the effect of medicines for Parkinson's disease and restless legs syndrome (e.g., levodopa).
This medicine may cause an abnormality in the electrocardiogram (ECG) that shows that it is necessary for an electrical impulse to travel through a certain part of the heart for a longer period (known as "prolongation of the QT interval"). Other medicines that have this effect include some medicines used to treat heart rhythm or to treat infections, in addition to other antipsychotics.
If you are prone to seizures, this medicine may increase your chances of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infections, in addition to other antipsychotics.
Paliperidona Teva should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
Using Paliperidona Teva with alcohol
Alcohol should be avoided.
Pregnancy, breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. You should not use this medicine during pregnancy unless you have discussed it with your doctor. The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last trimester of pregnancy (the last three months of pregnancy): shaking, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.
This medicine can pass from mother to child through breast milk and may harm the baby. Therefore, you should not breast-feed while using this medicine.
Driving and using machines
During treatment with this medicine, dizziness, extreme fatigue and vision problems (see section 4) may occur. This should be taken into account when maximum attention is required, e.g., when driving or operating machinery.
Paliperidona Teva contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is, essentially "sodium-free".
Your doctor or another healthcare professional will administer this medicine to you. Your doctor will tell you when you should receive the next injection. It is important that you do not miss any of the scheduled doses. If you cannot attend your appointment with the doctor, make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medicine in the upper arm approximately one week apart. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
If your doctor is switching you from risperidone long-acting injection to this medicine, you will receive the first injection of this medicine (of 25 mg to 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
Depending on your symptoms, the doctor may increase or decrease the amount of medicine you receive at a dose level at the time of the scheduled monthly injection.
Patient with kidney problems
Your doctor may adjust the dose of this medicine according to your kidney function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medicine if you have moderate or severe kidney problems.
Elderly patients
Your doctor may reduce the dose of this medicine if your kidney function is decreased.
If you use more Paliperidona Teva than you should
You will receive this medicine under medical supervision; it is, therefore, unlikely that you will receive an excessive dose.
Patient who have received an overdose of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heart rate, low blood pressure, abnormalities in the electrocardiogram (heart tracing), or slow or abnormal movements of the face, body, arms or legs.
If you stop using Paliperidona Teva
If you stop receiving your injections, the effects of the medicine will be lost. You should not stop using this medicine unless your doctor tells you to, as your symptoms may come back.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Tell your doctor immediately if:
The following adverse effects may occur:
Very Common Adverse Effects: may affect more than 1 in 10 patients
Common Adverse Effects: may affect up to 1 in 10 patients
Uncommon Adverse Effects: may affect up to 1 in 100 patients
Rare Adverse Effects: may affect up to 1 in 1,000 patients
Frequency Not Known: cannot be estimated from the available data
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the pre-filled syringe and on the box after "CAD or EXP". The expiration date is the last day of the month indicated.
This medicine does not require any special storage conditions.
Medicines should not be thrown down the drain or into the trash. Deposit the containers and medicines you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
Composition of Paliperidone Teva
The active ingredient is paliperidone
Each Paliperidone Teva 50 mg pre-filled syringe contains 78 mg of paliperidone palmitate in 0.5 ml
Each Paliperidone Teva 75 mg pre-filled syringe contains 117 mg of paliperidone palmitate in 0.75 ml.
Each Paliperidone Teva 100 mg pre-filled syringe contains 156 mg of paliperidone palmitate in 1 ml.
Each Paliperidone Teva 150 mg pre-filled syringe contains 234 mg of paliperidone palmitate in 1.5 ml.
Treatment Initiation Pack:
Each Paliperidone Teva 100 mg pre-filled syringe contains 156 mg of paliperidone palmitate in 1 ml.
Each Paliperidone Teva 150 mg pre-filled syringe contains 234 mg of paliperidone palmitate in 1.5 ml.
The other components are:
Polysorbate 20
Macrogol 4000
Citric acid monohydrate
Disodium phosphate
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide (for pH adjustment)
Water for injectable preparations
Appearance and Container Contents of the Product
Paliperidone Teva is a white to off-white prolonged-release injectable suspension, which comes in a pre-filled syringe (prolonged-release injection)
Each container contains 1 pre-filled syringe and 2 safety needles.
Treatment Initiation Pack:
Each container contains 1 Paliperidone Teva 150 mg and 1 Paliperidone Teva 100 mg.
Only certain pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Manufacturer:
Actavis Group PTC ehf.
Dalshraun 1,
Hafnarfjörður 220.
Iceland
For further information on this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Teva Pharma, S.L.U
C/ Anabel Segura, 11, Edifício Albatros B, 1ª planta,
Alcobendas, 28108, Madrid (Spain)
This medicinal product is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Germany: | Paliperidon-ratiopharm 25 mg Depot-Injektionssuspension Paliperidon-ratiopharm 50 mg Depot-Injektionssuspension Paliperidon-ratiopharm 75 mg Depot-Injektionssuspension Paliperidon-ratiopharm 100 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg und 100 mg Depot-Injektionssuspension |
Austria: | Paliperidon ratiopharm 25 mg Depot-Injektionssuspension Paliperidon ratiopharm 50 mg Depot-Injektionssuspension Paliperidon ratiopharm 75 mg Depot-Injektionssuspension Paliperidon ratiopharm 100 mg Depot-Injektionssuspension Paliperidon ratiopharm 150 mg Depot-Injektionssuspension Paliperidon ratiopharm Starterpackung 100 mg und Paliperidon ratiopharm 150 mg Depot-Injektionssuspension |
Belgium | Paliperidone Teva 25 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 50 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 75 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 100 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 150 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 150 mg & 100 mg suspensie voor injectie met verlengde afgifte/suspension injectable à libération prolongée/Depot-Injektionssuspension |
Bulgaria: | ??????????? ???? 75 mg ??????????? ????????? ? ???????? ????????????? ??????????? ???? 100 mg ??????????? ????????? ? ???????? ????????????? ??????????? ???? 150 mg ??????????? ????????? ? ???????? ????????????? |
Croatia: | Paliperidon Teva 50 mg suspenzija za injekciju s produljenim oslobadanjem Paliperidon Teva 75 mg suspenzija za injekciju s produljenim oslobadanjem Paliperidon Teva 100 mg suspenzija za injekciju s produljenim oslobadanjem Paliperidon Teva 150 mg suspenzija za injekciju s produljenim oslobadanjem |
Cyprus: | Paliperidone/Teva Pharma 75 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma100 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma 150 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης |
Denmark: | Paliperidon Teva |
Estonia: | Paliperidone Teva |
Finland: | Paliperidone ratiopharm 25 mg injektioneste, depotsuspensio Paliperidone ratiopharm 50 mg injektioneste, depotsuspensio Paliperidone ratiopharm 75 mg injektioneste, depotsuspensio Paliperidone ratiopharm 100 mg injektioneste, depotsuspensio Paliperidone ratiopharm 150 mg injektioneste, depotsuspensio Paliperidone ratiopharm 100 mg + 150 mg injektioneste, depotsuspensio |
France: | PALIPERIDONE TEVA 25mg suspension injectable à libération prolongée PALIPERIDONE TEVA 50mg suspension injectable à libération prolongée PALIPERIDONE TEVA 75mg suspension injectable à libération prolongée PALIPERIDONE TEVA 100mg suspension injectable à libération prolongée PALIPERIDONE TEVA 150mg suspension injectable à libération prolongée |
Greece: | Paliperidone/Teva Pharma 75 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma 100 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma 150 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης |
Hungary: | Paliperidon Teva 25 mg retard szuszpenziós injekció Paliperidon Teva 50 mg retard szuszpenziós injekció Paliperidon Teva 75 mg retard szuszpenziós injekció Paliperidon Teva 100 mg retard szuszpenziós injekció Paliperidon Teva 150 mg retard szuszpenziós Injekció Paliperidon Teva 150 mg és 100 mg retard szuszpenziós injekció |
Iceland: | Paliperidon Teva |
Ireland: | Paliperidone Teva 25mg Prolonged-release Suspension for Injection Paliperidone Teva 50mg Prolonged-release Suspension for Injection Paliperidone Teva 75mg Prolonged-release Suspension for Injection Paliperidone Teva 100mg Prolonged-release Suspension for Injection Paliperidone Teva 150mg Prolonged-release Suspension for Injection Paliperidone Teva 150mg and 100mg Prolonged-release Suspension for Injection |
Italy: | Paliperidone Teva Italia |
Latvia: | Paliperidone Teva 75 mg ilgstošas darbibas suspensija injekcijam Paliperidone Teva 100 mg ilgstošas darbibas suspensija injekcijam Palieridone Teva 150 mg ilgstošas darbibas suspensija injekcijam |
Lithuania: | Paliperidone Teva 50 mg pailginto atpalaidavimo injekcine suspensija Paliperidone Teva 75 mg pailginto atpalaidavimo injekcine suspensija Paliperidone Teva 100 mg pailginto atpalaidavimo injekcine suspensija Palieridone Teva 150 mg pailginto atpalaidavimo injekcine suspensija |
Luxembourg: | Paliperidon-ratiopharm 25 mg Depot-Injektionssuspension Paliperidon-ratiopharm 50 mg Depot-Injektionssuspension Paliperidon-ratiopharm 75 mg Depot-Injektionssuspension Paliperidon-ratiopharm 100 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg und 100 mg Depot-Injektionssuspension |
Netherlands: | Paliperidon Teva 25 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 50 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 75 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 100 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 150 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 150 mg, en 100 mg, suspensie voor injectie met verlengde afgifte |
Norway: | Paliperidon Teva |
Poland: | Paliperidone Teva |
Portugal: | Paliperidona Teva |
Romania: | Paliperidona Teva 50 mg suspensie injectabila cu eliberare prelungita Paliperidona Teva 75 mg suspensie injectabila cu eliberare prelungita Paliperidona Teva 100 mg suspensie injectabila cu eliberare prelungita Paliperidona Teva 150 mg suspensie injectabila cu eliberare prelungita |
Slovakia: | Paliperidón Teva 25 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 50 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 75 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 100 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 150 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 150 mg injekcná suspenzia s predlženým uvolnovaním a Paliperidón Teva 100 mg injekcná suspenzia s predlženým uvolnovaním |
Slovenia: | Paliperidon Teva 50 mg suspenzija s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 75 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 100 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 150 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 150 mg in 100 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje |
Spain: | Paliperidona Teva 50 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 75 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 100 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 150 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 150 mg y Paliperidona Teva 100 mg suspensión inyectable de liberación prolongada EFG |
Sweden: | Paliperidon Teva |
United Kingdom (Northern Ireland): | Paliperidone Teva 25 mg Prolonged-release Suspension for Injection Paliperidone Teva 50 mg Prolonged-release Suspension for Injection Paliperidone Teva 75 mg Prolonged-release Suspension for Injection Paliperidone Teva 100 mg Prolonged-release Suspension for Injection Paliperidone Teva 150 mg Prolonged-release Suspension for Injection Paliperidone Teva 150 mg and 100 mg Prolonged-release Suspension for Injection Treatment Initiation Pack |
Date of last revision of this leaflet:February 2024
Other sources of information
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
This information is intended solely for healthcare professionals and should be read in conjunction with the complete prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use. It should be visually inspected for any foreign particles before administration. Do not use the product if the syringe is not visually free of foreign particles.
The container contains a pre-filled syringe and two safety needles (one 22-gauge, 1½-inch [38.1 mm x 0.72 mm] needle and one 23-gauge, 1-inch [25.4 mm x 0.64 mm] needle) for intramuscular injection. Paliperidone Teva is also available in a treatment initiation pack containing two pre-filled syringes (150 mg + 100 mg) and two additional safety needles.
The first initiation dose of Paliperidone Teva (150 mg) is administered on Day 1 in the deltoid muscle using the needle for deltoid muscle injection. The second initiation dose of Paliperidone Teva (100 mg) is administered in the deltoid muscle one week later (Day 8) using the needle for deltoid muscle injection.
If a patient is being switched from risperidone long-acting injection to Paliperidone Teva, the first injection of Paliperidone Teva (dose range of 25 mg to 150 mg) may be administered in the deltoid muscle or gluteal muscle, using the appropriate needle for the injection site, at the time of the next scheduled injection.
Subsequent maintenance injections can be administered in either the deltoid muscle or gluteal muscle using the appropriate needle for the injection site.
In the case of injection into the deltoid muscle, if the patient weighs <90 kg, use the 23-gauge, 1-inch (25.4 mm x 0.64 mm) needle (needle with blue hub); if patient weighs ≥ 90 22-gauge, 1½-inch (38.1 0.72 gray hub).< p>
In the case of injection into the gluteal muscle, use the 22-gauge, 1½-inch (38.1 mm x 0.72 mm) needle (needle with gray hub).
8.a
8.b
8.c
The disposal of unused medicinal products and all materials that have come into contact with them will be carried out in accordance with local regulations.